The company said on Monday it will voluntarily withdraw its lung cancer therapy from the US after it failed to meet the main goal in a late-stage study.
The FDA has approved FoundationOne® Liquid CDx as a companion diagnostic for mobocertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Takeda's Exkivity receives NICE recommendation for rare form of lung cancer pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.